Ann Mills and Rick ChildsWelcome to Triple Therapy for Hepatitis C. This site is dedicated to providing caregivers, patients and families the best information, news and resources for the new triple therapy for hepatitis C.

Triple therapy, the combination of Incivek (telaprevir) or Victrelis (boceprevir) with ribavirin and pegylated interferon, is a “true game changer,” according to the College of American Pathologists. “They (the therapy) promise to transform the treatment of hepatitis C, the most common chronic bloodborne viral infection in the U.S.”

That is the good news and it is very good news indeed. However, the side effects of triple therapy can be so devastating that they too can be “game changers,” changing forever your relationship with your loved ones.

We know this to be true. One of the two authors of this site, Ann Mills, is the caregiver for her husband, Rick Childs, who is currently undergoing triple therapy for hepatitis C.

The therapy has been a wrecking ball, affecting every aspect of their life together. This site builds upon their experiences to hopefully provide you, the caregiver and/or patient with information and tips for managing this shattering period of your life.

As Rick begins to feel better, we hope he will contribute to the site. However, he fully endorses this effort to share his experience and Ann’s with others.  His hope and our own is that his experience and Ann’s can help other families facing this life-giving, but brutal experience.

In addition, by calling attention to the concerns of caregivers of patients with hepatitis C undergoing triple therapy, we hope to bridge the gap between the medical community, patients and their families.  With all the good will and best intentions in the world, the medical community has not had extensive experience with triple therapy for hepatitis C.  The therapy is too new.

Please explore the site and please feel free to contact us with any comments, criticisms or especially any advice that might be helpful to other caregivers and patients.

Comments are closed.